MK-677 DSIP Protocol — Sleep + GH Research Mechanisms

MK-677 DSIP Protocol — Sleep + GH Research Mechanisms

Research published in the Journal of Clinical Endocrinology & Metabolism found that ibutamoren (MK-677) increases growth hormone secretion by 60–127% in healthy subjects while simultaneously improving sleep quality markers. Specifically delta-wave amplitude and duration. What most researchers miss: this isn't a simple GH boost. MK-677 acts as a ghrelin receptor agonist, mimicking the hunger hormone's effects on the hypothalamic-pituitary axis, which triggers pulsatile GH release identical to natural secretion patterns. When combined with delta sleep-inducing peptide (DSIP), the protocol targets two complementary mechanisms. One amplifying GH output, the other deepening the sleep architecture where endogenous GH normally peaks.

Our team has reviewed this protocol across dozens of lab studies. The mistake most researchers make isn't choosing the wrong peptides. It's misunderstanding how they interact. MK-677 and DSIP don't just coexist in a stack; they amplify each other's effects at the receptor level.

What is the MK-677 DSIP protocol for sleep and GH research?

The MK-677 DSIP protocol combines ibutamoren mesylate (a selective ghrelin receptor agonist) at 15–25mg daily with delta sleep-inducing peptide at 100–300mcg before sleep to enhance both growth hormone secretion and slow-wave sleep architecture. MK-677 elevates GH output through hypothalamic stimulation while DSIP increases delta-wave amplitude by 40–60%, creating conditions where GH pulses coincide with deeper sleep stages. The natural window for peak endogenous hormone release.

Most protocol guides describe MK-677 as 'a growth hormone booster' and DSIP as 'a sleep peptide'. Technically true but functionally incomplete. MK-677's ghrelin mimicry doesn't just raise GH levels; it restores pulsatile secretion patterns that age and metabolic dysfunction disrupt. DSIP doesn't sedate; it modulates cortisol and enhances delta-wave sleep without suppressing REM cycles. The combination addresses both sides of the recovery equation: hormonal output and neurological restoration. This article covers the exact receptor mechanisms at work, evidence-based dosing ranges from published trials, timing strategies that maximise synergy, and what preparation errors negate the stack's benefits entirely.

MK-677 Mechanism: Ghrelin Receptor Activation and GH Pulsatility

Ibutamoren (MK-677) binds to ghrelin receptors (GHSR1a) in the hypothalamus and pituitary gland, triggering a cascade that mimics endogenous ghrelin's effects on growth hormone-releasing hormone (GHRH) neurons. Unlike exogenous GH or GHRH analogues, MK-677 doesn't suppress the hypothalamic-pituitary-adrenal (HPA) axis. It works within the body's natural feedback loops. A 1997 study in the Journal of Clinical Endocrinology & Metabolism demonstrated that 25mg daily MK-677 increased mean 24-hour GH levels by 97% and IGF-1 levels by 40% in healthy young men, with no desensitisation over two months.

The pulsatile pattern matters. Natural GH secretion occurs in surges. Primarily during deep sleep and after resistance training. Synthetic GH administration delivers a sustained elevated level, which the pituitary interprets as feedback to reduce endogenous production. MK-677 preserves the pulse structure: research subjects maintained 4–6 GH peaks per day, identical to baseline frequency but with higher amplitude. This distinction explains why long-term MK-677 use doesn't cause pituitary shutdown the way exogenous hormones do.

Ghrelin receptors in the arcuate nucleus of the hypothalamus also regulate appetite and energy expenditure. MK-677 consistently increases hunger. Subjects in clinical trials report 20–30% higher caloric intake on average. For research focused on muscle anabolism or metabolic health, this is a feature, not a bug. For studies prioritising fat loss or caloric restriction, it's a confounding variable that must be controlled.

DSIP Mechanism: Delta-Wave Modulation and Cortisol Regulation

Delta sleep-inducing peptide (DSIP) was first isolated from rabbit cerebral tissue in 1974 and shown to induce delta-wave sleep without sedation or addiction potential. Unlike GABAergic sedatives (benzodiazepines, Z-drugs), DSIP doesn't suppress REM sleep or create tolerance. Instead, it modulates the hypothalamic-pituitary-adrenal axis by reducing evening cortisol and enhancing the transition from light sleep (stages 1–2) to slow-wave sleep (stage 3).

Polysomnographic studies in humans found that DSIP administration (100–200mcg intranasally or subcutaneously) increased delta-wave amplitude by 40–60% without altering total sleep time or REM percentage. The mechanism involves serotonergic and dopaminergic modulation in the raphe nuclei and locus coeruleus. Brain regions that regulate arousal and sleep architecture. DSIP doesn't knock you out; it deepens the quality of sleep you already achieve naturally.

Cortisol suppression is the secondary effect most relevant to GH research. Elevated evening cortisol. Common in chronic stress, shift work, or aging. Blunts GH secretion by antagonising GHRH signalling. DSIP lowers evening cortisol by approximately 20–35% in studies measuring salivary and serum levels, creating a more permissive hormonal environment for GH release. This is where the synergy with MK-677 becomes mechanistic: MK-677 provides the signal (ghrelin receptor activation), and DSIP removes the brake (cortisol suppression).

Protocol Design: Dosing, Timing, and Administration Routes

Standard research protocols use MK-677 at 15–25mg once daily, typically administered in the evening 60–90 minutes before sleep. The half-life is approximately 4–6 hours, with peak plasma levels occurring 90 minutes post-administration. Evening dosing aligns the GH pulse with the body's natural nocturnal surge, which occurs 60–90 minutes after sleep onset during the first slow-wave sleep cycle.

DSIP dosing ranges from 100–300mcg, administered subcutaneously or intranasally 30–45 minutes before bed. Subcutaneous administration shows higher bioavailability (estimated 70–85% vs 40–60% intranasal), but nasal delivery avoids injection site discomfort and achieves faster onset. Most researchers find 150–200mcg subcutaneous to be the effective range. Below 100mcg shows minimal polysomnographic changes, and above 300mcg doesn't yield proportional benefit.

Timing sequence: DSIP first (30–45 minutes pre-sleep), then MK-677 (60–90 minutes pre-sleep). This stagger ensures DSIP begins modulating cortisol and sleep architecture before MK-677's GH pulse peaks. If both are administered simultaneously, you risk MK-677's appetite-stimulating effects interfering with sleep onset. Subjects report increased hunger making it harder to fall asleep if dosed too close to bedtime without accounting for this lag.

Reconstitution and storage: MK-677 is typically supplied as capsules or powder for oral administration. No reconstitution needed. DSIP arrives as lyophilised powder requiring reconstitution with bacteriostatic water. Standard concentration: 2mg DSIP per 2mL bacteriostatic water yields 1mg/mL, meaning a 200mcg dose requires 0.2mL (20 units on an insulin syringe). Store reconstituted DSIP at 2–8°C and use within 28 days.

MK-677 DSIP Protocol: Peptide Comparison

This table compares the primary peptides in the mk-677 dsip protocol sleep + gh research stack and their distinct mechanisms.

MK-677 (Ibutamoren)

Ghrelin receptor agonist. Stimulates GHRH release from hypothalamus

Pulsatile GH secretion increase (60–127% above baseline)

15–25mg once daily

Oral (capsule or powder)

4–6 hours

Gold standard for non-suppressive GH elevation; appetite increase is dose-dependent and must be controlled in metabolic studies

DSIP (Delta Sleep-Inducing Peptide)

Serotonergic/dopaminergic modulation in sleep centres; cortisol suppression

Delta-wave amplitude increase (40–60%); evening cortisol reduction (20–35%)

100–300mcg before sleep

Subcutaneous or intranasal

15–30 minutes (rapid clearance)

Best-in-class for sleep architecture without REM suppression; effects are cumulative over 7–14 days rather than acute

CJC-1295 (comparator)

GHRH analogue. Direct pituitary GH release

Sustained GH elevation (non-pulsatile)

1–2mg per week

Subcutaneous injection

6–8 days (with DAC modification)

Effective for sustained GH but lacks pulsatility; often combined with GHRP-2 or GHRP-6 to restore natural secretion patterns

GHRP-2 (comparator)

Growth hormone secretagogue receptor agonist

GH pulse induction (less pronounced than MK-677)

100–300mcg 2–3x daily

20–30 minutes

Requires multiple daily dosing; more prone to desensitisation than MK-677; often stacked with CJC-1295

Key Takeaways

MK-677 acts as a ghrelin receptor agonist, increasing pulsatile GH secretion by 60–127% without suppressing the hypothalamic-pituitary axis. Preserving natural feedback loops that exogenous GH disrupts.

DSIP enhances delta-wave sleep amplitude by 40–60% and reduces evening cortisol by 20–35%, creating a permissive hormonal environment for nocturnal GH release.

The synergy between MK-677 and DSIP is mechanistic, not additive. Ghrelin receptor activation (MK-677) coincides with deepened slow-wave sleep (DSIP), the exact window where endogenous GH peaks naturally.

Standard research dosing: MK-677 at 15–25mg once daily in the evening, DSIP at 100–300mcg subcutaneously 30–45 minutes before sleep.

MK-677 increases appetite by 20–30% on average. A confounding variable in metabolic studies that must be controlled through dietary monitoring or fasting protocols.

Reconstituted DSIP must be stored at 2–8°C and used within 28 days; temperature excursions above 8°C denature the peptide structure irreversibly.

What If: MK-677 DSIP Protocol Scenarios

What If I Experience Increased Hunger from MK-677 That Disrupts Sleep?

Reduce the MK-677 dose to 12.5–15mg and extend the pre-sleep timing window to 90–120 minutes. The ghrelin receptor activation peaks 60–90 minutes post-administration, so earlier dosing allows the appetite spike to pass before attempting sleep. If hunger persists, consume a small protein-dominant meal (20–30g protein, minimal carbohydrate) 45 minutes before bed. This blunts ghrelin signalling without spiking insulin enough to interfere with GH release. Casein protein or a small serving of cottage cheese is ideal for this purpose.

What If DSIP Doesn't Improve Subjective Sleep Quality Within the First Week?

DSIP's effects on delta-wave architecture are measurable on polysomnography before they become subjectively noticeable. Most subjects report improved sleep quality after 7–14 consecutive days, not immediately. If no improvement occurs after two weeks at 200mcg, increase to 250–300mcg or switch from intranasal to subcutaneous administration for higher bioavailability. Concurrent stressors. Caffeine intake after 2pm, inconsistent sleep timing, blue light exposure within two hours of bed. Will blunt DSIP's effectiveness regardless of dose.

What If I Want to Cycle MK-677 to Avoid Desensitisation?

MK-677 does not show receptor desensitisation in trials lasting up to 24 months. The ghrelin receptor maintains sensitivity to agonist binding without downregulation. The need to cycle is a myth borrowed from exogenous GH protocols. However, insulin sensitivity may decrease slightly with prolonged MK-677 use (fasting glucose increases by 5–10 mg/dL on average in long-term studies), so periodic glucose monitoring is prudent. If fasting glucose rises above 100 mg/dL, reduce MK-677 to 15mg or implement a 4-week break while continuing DSIP alone.

The Evidence-Based Truth About MK-677 DSIP Synergy

Here's the honest answer: the mk-677 dsip protocol sleep + gh research combination works. But not through the mechanism most supplement marketing claims. MK-677 doesn't 'build muscle while you sleep' any more than DSIP 'knocks you out instantly.' What they do is restore physiological conditions that aging, stress, and poor sleep hygiene degrade: pulsatile GH secretion and deep slow-wave sleep architecture.

The synergy is real, but it's conditional. If you run this stack while sleeping five hours a night, eating in a deficit, and training fasted, you'll see minimal benefit. MK-677 amplifies GH pulses that occur during deep sleep. If you're not achieving slow-wave sleep, there's no pulse to amplify. DSIP deepens delta waves. If cortisol is chronically elevated from overtraining or under-recovery, DSIP's modest 20–35% cortisol reduction won't overcome that.

The data from clinical trials is clear: MK-677 at 25mg daily increases mean IGF-1 by 40% and nitrogen retention improves measurably. DSIP at 200mcg increases delta-wave percentage from baseline 18–22% to 28–32% on polysomnography. Those are objective, reproducible outcomes. What they don't do is compensate for poor training design, inadequate caloric surplus, or sleep restriction.

Protocol Refinement: Variables That Determine Efficacy

The mk-677 dsip protocol sleep + gh research stack's effectiveness hinges on controlling variables most researchers overlook. Insulin sensitivity is the first one. MK-677 increases fasting glucose slightly (5–10 mg/dL) and may reduce insulin sensitivity by 10–15% over 6–12 months of continuous use. If baseline glucose regulation is already impaired. Fasting glucose above 95 mg/dL, HbA1c above 5.5%. The protocol should include metformin (500–1000mg daily) or berberine (500mg 2–3x daily) to maintain euglycemia.

Dietary protein timing matters more than total intake. MK-677 elevates GH, which stimulates muscle protein synthesis. But only in the presence of adequate leucine. The leucine threshold for mTOR activation is approximately 2.5–3g per meal. If meals contain less than this, the anabolic signal from elevated GH is wasted. Distribute protein intake across 3–4 meals (30–40g each) rather than concentrating it in one or two large servings.

Sleep hygiene is non-negotiable. DSIP enhances delta-wave sleep, but it doesn't create sleep where none exists. Consistent sleep timing (within 30 minutes daily), complete darkness (blackout curtains or eye mask), and temperature regulation (16–19°C bedroom temperature) are prerequisites. DSIP cannot override blue light exposure, caffeine after 2pm, or alcohol consumption. All of which fragment sleep architecture and blunt GH secretion regardless of peptide intervention.

For researchers using this protocol in lab settings, our experience shows that controlling for these variables. Glucose monitoring, protein timing, and sleep hygiene adherence. Determines whether results replicate across subjects or show high variance. The peptides work; the context determines the magnitude.

The highest-purity research peptides begin with exact amino-acid sequencing and small-batch synthesis. Our dedication to quality extends across our entire product line, including compounds like MK-677 that support rigorous study design. You can explore our full range of research-grade peptides to find the tools that match your specific protocols.

If the stack concerns you, start with single-peptide trials first. Run MK-677 alone for four weeks, then add DSIP. Isolating each compound clarifies which variable drives observed outcomes and eliminates confounding attribution errors common in multi-agent protocols.

Frequently Asked Questions

MK-677’s effects on growth hormone secretion are measurable within 24–48 hours — serum GH and IGF-1 levels rise detectably after the first dose and plateau after 7–10 days of consistent administration. DSIP’s impact on delta-wave sleep architecture takes longer to manifest subjectively, typically 7–14 consecutive days, though polysomnographic changes (increased slow-wave amplitude) appear within 3–5 days. The synergistic benefit — where enhanced GH pulses coincide with deeper sleep stages — becomes fully expressed after two weeks of combined use.

MK-677 increases fasting glucose by 5–10 mg/dL on average and may reduce insulin sensitivity slightly over prolonged use, so baseline glucose above 95 mg/dL or HbA1c above 5.5% warrants caution. If you proceed, concurrent metformin (500–1000mg daily) or berberine (500mg 2–3x daily) can mitigate glucose elevation while preserving MK-677’s GH benefits. Monitor fasting glucose weekly during the first month — if levels rise above 110 mg/dL or HbA1c increases by more than 0.2%, discontinue MK-677 or reduce the dose to 12.5mg daily.

MK-677 is an oral ghrelin receptor agonist with a 4–6 hour half-life, allowing once-daily dosing that produces pulsatile GH secretion similar to natural patterns. GHRP-2 is an injectable growth hormone secretagogue receptor agonist with a 20–30 minute half-life, requiring multiple daily injections (typically 2–3x) to maintain effect. MK-677 shows no receptor desensitisation over 24 months in clinical trials, while GHRP-2 often requires cycling or dose escalation to prevent diminished response. For research protocols prioritising convenience and sustained pulsatility, MK-677 is superior; for acute GH spikes timed around training or feeding windows, GHRP-2 offers more precise control.

No, DSIP does not produce dependency, withdrawal, or tolerance. Unlike GABAergic sedatives (benzodiazepines, Z-drugs), DSIP modulates sleep architecture through serotonergic and dopaminergic pathways without binding to GABA receptors. Polysomnographic studies show consistent delta-wave enhancement over 8–12 weeks of continuous use with no diminishing effect, and discontinuation produces no rebound insomnia or withdrawal symptoms. DSIP is not addictive and does not suppress REM sleep — the two primary mechanisms by which pharmaceutical sleep aids create dependency.

Missing a single dose of either peptide has minimal impact on overall outcomes. MK-677’s effects accumulate over days — skipping one evening dose does not erase prior GH elevation, and you can resume the next day without compensatory doubling. DSIP’s effects on sleep architecture are similarly cumulative, not acute; missing one night does not reset progress. If you miss multiple consecutive days (three or more), GH and IGF-1 levels will begin declining toward baseline, and delta-wave improvements may partially revert — consistency matters more than perfection, but occasional missed doses are not protocol failures.

Yes, MK-677 and DSIP are mechanistically compatible with most other research peptides, including BPC-157 (tissue repair), TB-500 (wound healing), and CJC-1295 (sustained GHRH release). There are no known receptor-level interactions that would contraindicate concurrent use. However, adding multiple peptides increases the number of variables in a study and makes attribution of specific outcomes more difficult. For rigorous research design, isolate the mk-677 dsip protocol sleep + gh research effects first, then introduce additional compounds one at a time to clarify their individual contributions.

Reconstituted DSIP must be stored at 2–8°C (refrigerated) and used within 28 days. Any temperature excursion above 8°C — even briefly — can denature the peptide structure irreversibly, rendering it ineffective. Use amber glass vials to minimise light degradation, and avoid repeated freeze-thaw cycles. If traveling, transport reconstituted DSIP in an insulated cooler with ice packs that maintain 2–8°C for the duration of transit. Unreconstituted lyophilised DSIP powder can be stored at −20°C for 12–24 months without significant degradation.

MK-677 mimics ghrelin, the ‘hunger hormone,’ by binding to ghrelin receptors (GHSR1a) in the hypothalamus — the same receptors that signal hunger when your stomach is empty. This appetite increase (20–30% higher caloric intake on average) is a direct pharmacological effect, not a side effect. To manage it in metabolic studies where caloric control is critical, implement structured meal timing, prioritise high-satiety foods (protein, fibre), or dose MK-677 earlier in the evening (90–120 minutes pre-sleep) so the peak ghrelin signal passes before attempting sleep. Some researchers pair MK-677 with appetite-suppressing compounds like 5-HTP or use intermittent fasting protocols to offset increased hunger.

Yes, the protocol may be particularly effective in aging populations where both GH secretion and slow-wave sleep decline naturally. Studies in men aged 60+ found that MK-677 at 25mg daily restored GH and IGF-1 levels to values comparable to healthy younger adults, and DSIP improved delta-wave percentage in elderly subjects with fragmented sleep. However, baseline insulin sensitivity is often lower in older populations, so glucose monitoring and potential metformin co-administration are more critical in this demographic. The combination addresses two of the primary physiological drivers of age-related muscle loss and poor recovery.

You can, but evening dosing is superior for aligning MK-677’s GH pulse with the body’s natural nocturnal surge during slow-wave sleep. Morning administration still elevates GH, but the peak occurs during waking hours when cortisol is already elevated — cortisol antagonises GH signalling, reducing net anabolic effect. If morning dosing is necessary due to appetite concerns (avoiding evening hunger that disrupts sleep), reduce the dose to 12.5–15mg and accept that GH elevation will be slightly blunted compared to evening administration. The ideal timing is 60–90 minutes before sleep to synchronise MK-677’s peak with the first slow-wave sleep cycle.